Standard BioTools Stockholders Approve Merger with SomaLogic

Standard BioTools Stockholders Approve Merger

SOUTH SAN FRANCISCO, Calif., January 4, 2024 -- Standard BioTools

Inc. (Nasdaq: LAB), driven by a bold purpose - Unleashing tools to accelerate breakthroughs in human health, today announced

that its stockholders voted to approve all proposals required to be approved in connection with the pending merger with SomaLogic (Nasdaq:

SLGC) at its Special Meeting of Stockholders.

"We are pleased with the outcome of today's Special Meeting

and thank our stockholders for their support for this merger," said Michael Egholm, PhD, President and Chief Executive Officer of

Standard BioTools. "Together with SomaLogic, we will have an expanded platform to better serve our customers and we believe we will

be able to deliver significant shareholder value through enhanced scale and a strengthened balance sheet to fuel future growth."

Standard BioTools will file the final vote results, as certified by

the independent inspector of election, on a Form 8-K with the U.S. Securities and Exchange Commission.

The merger is expected to close on January 5, 2024, subject to

satisfaction of certain customary closing conditions.

About Standard BioTools Inc.

Standard BioTools Inc. (Nasdaq:LAB), previously known as Fluidigm

Corporation, is driven by a bold purpose - Unleashing tools to accelerate breakthroughs in human health. Standard BioTools has

an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster

and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary

mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools

works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide,

focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. Learn

more at www.standardbio.com or connect with us on Twitter , Facebook , LinkedIn, and YouTube . Standard

BioTools, the Standard BioTools logo, Fluidigm, the Fluidigm logo, "Unleashing tools to accelerate breakthroughs in human health,"

Hyperion, Hyperion XTi, XTi, and X9 are trademarks and/or registered trademarks of Standard BioTools Inc. or its affiliates in the United

States and/or other countries. All other trademarks are the sole property of their respective owners. Standard BioTools products are

provided for Research Use Only. Not for use in diagnostic procedures.

Forward-Looking Statements

release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of

1995. Such statements are based upon current plans, estimates and expectations of the management of Standard BioTools and

SomaLogic that are subject to various risks and uncertainties that could cause actual results to differ materially from such

statements, many of which are beyond the control of Standard BioTools and SomaLogic. All statements other than statements of

historical fact (including statements containing the words "believes," "plans," "anticipates,"

"expects," "estimates" and similar expressions) are statements that could be deemed forward-looking

statements, although not all forward-looking statements contain these identifying words. Readers should not place undue reliance on

these forward-looking statements. Forward-looking statements may include statements regarding the expected timing of the closing of

the merger; the ability of the parties to complete the merger considering the various closing conditions; and any assumptions

underlying any of the foregoing. Statements regarding future events are based on the parties' current expectations and are

necessarily subject to associated risks related to, among other things, (i) the risk that the merger may not be completed in a

timely manner or at all, which may adversely affect Standard BioTools' and SomaLogic's businesses and the price of their

respective securities; (ii) uncertainties as to the timing of the consummation of the merger and the potential failure to

satisfy the conditions to the consummation of the merger; (iii) the merger may involve unexpected costs, liabilities or delays;

(iv) the effect of the announcement, pendency or completion of the merger on the ability of Standard BioTools

or SomaLogic to retain and hire key personnel and maintain relationships with customers, suppliers and others with

whom Standard BioTools or SomaLogic does business, or on Standard BioTools' or SomaLogic's operating

results and business generally; (v) Standard BioTools' or SomaLogic's respective businesses may suffer as a result

of uncertainty surrounding the merger and disruption of management's attention due to the merger; (vi) the outcome of any

legal proceedings related to the merger or otherwise, or the impact of the merger thereupon; (vii) Standard

BioTools or SomaLogic may be adversely affected by other economic, business and competitive factors; (viii) the

occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement and the

merger; (ix) restrictions during the pendency of the merger that may impact Standard BioTools' or SomaLogic's

ability to pursue certain business opportunities or strategic transactions; (x) the risk that Standard

BioTools or SomaLogic may be unable to obtain governmental and regulatory approvals required for the consummation of

the merger, or that required governmental and regulatory approvals may delay the consummation of the merger, result in the

imposition of conditions that could reduce the anticipated benefits from the merger or cause the parties to abandon the merger;

(xi) risks that the anticipated benefits of the merger or other commercial opportunities may otherwise not be fully realized or

may take longer to realize than expected; (xii) the impact of legislative, regulatory, economic, competitive and technological

changes; (xiii) risks relating to the value of the Standard BioTools shares to be issued in the merger;

(xiv) the risk that post-closing integration of the merger may not occur as anticipated or the combined company may not be able

to achieve the benefits expected from the merger, as well as the risk of potential delays, challenges and expenses associated with

integrating the combined company's existing businesses; (xv) exposure to inflation, currency rate and interest rate

fluctuations, as well as fluctuations in the market price of Standard BioTools' and SomaLogic's traded securities;

(xvi) the lingering effects of the COVID-19 pandemic on Standard BioTools' and SomaLogic's industry and individual

companies, including on counterparties, the supply chain, the execution of research and development programs, access to financing

and the allocation of government resources; (xvii) the ability of Standard BioTools or SomaLogic to protect

and enforce intellectual property rights; and (xviii) the unpredictability and severity of catastrophic events, including, but

not limited to, acts of terrorism or outbreak of war or hostilities, as well as Standard BioTools' and SomaLogic's

response to any of the aforementioned factors. Therefore, actual results may differ materially and adversely from those expressed in

any forward-looking statements. For information regarding other related risks, see the "Risk Factors" section of

Standard BioTools' most recent quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission

(the "SEC") on November 7, 2023, on its most recent annual report on Form 10-K filed with

the SEC on March 14, 2023 and in Standard BioTools' other filings with the SEC, as well as the

"Risk Factors" section of SomaLogic's most recent quarterly report on Form 10-Q filed with

the SEC on November 8, 2023, on its most recent annual report on Form 10-K filed with

the SEC on March 28, 2023 and in SomaLogic's other filings with the SEC. The risks and

uncertainties described above and in the SEC filings cited above are not exclusive and further information

concerning Standard BioTools and SomaLogic and their respective businesses, including factors that potentially

could materially affect their respective businesses, financial conditions or operating results, may emerge from time to time.

Readers are urged to consider these factors carefully in evaluating these forward-looking statements, and not to place undue

reliance on any forward-looking statements. Any such forward-looking statements represent management's reasonable estimates

and beliefs as of the date of this press release. While Standard BioTools and SomaLogic may elect to update such

forward-looking statements at some point in the future, they disclaim any obligation to do so, other than as may be required by law,

even if subsequent events cause their views to change.

Nick Lamplough / Dan Moore / Tali Epstein

Collected Strategies